Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Forma Therapeutics Holdings, Inc. (FMTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/14/2022 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Third Amended and Restated Certificate of Incorporation",
"Second Amended and Restated By-Laws"
09/01/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Novo Nordisk A/S, NNUS New Dev, Inc. and Forma Therapeutics Holdings, Inc",
"Tender and Support Agreement, by and among Novo Nordisk A/S, NNUS New Dev, Inc. and certain Stockholders of Forma Therapeutics Holdings, Inc",
"Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders Bagsværd, Denmark and Watertown, Mass, US September 1, 2022"
08/05/2022 8-K Quarterly results
07/25/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
01/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/16/2021 8-K Quarterly results
12/13/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease complete, updated results to be presented at American Society of Hematology Annual Meeting December 11-14 Initial Phase 1 results presented in men with metastatic castration-resistant prostate cancer showed FT-7051 well-tolerated with evidence of clinical activity Olutasidenib combination data in relapsed/refractory acute myeloid leukemia to be presented at ASH Annual Meeting December 11-14"
10/07/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Forma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer"
08/13/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/14/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Strong pipeline progress amid challenging COVID-19 environment"
09/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors"
08/13/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
06/23/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy